Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

Results from two separate Phase 1 studies show sobetirome, a selective

thyroid hormone receptor beta agonist, reduced levels of low-density

lipoprotein versus placebo

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.

"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.

Study Results

Lipid-lowering effects in both single and multiple doses were seen in the randomized, double-blind, placebo-controlled Phase 1 studies of sobetirome. In the single dose study of 32 subjects, low-density lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects receiving up to 450 micrograms of sobetirome, compared to 2% in subjects who received placebo. The greatest reductions were observed 72 hours after dosing. In
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... WASHINGTON , May 5, 2015  Indianapolis-based ... adoption of its innovative line of products including ... solution for atraumatically accessing deep-seated brain abnormalities and ... have been completed at more than 50 institutions ... The technology has also been included in 12 ...
(Date:5/4/2015)... YORK , May 4, 2015 ... for granted. But for certain infants with rare, ... death are stark consequences of their impaired immune ... Medical Center have identified an important role for ... resulting from Mycobacterium tuberculosis, the bacterium causing tuberculosis ...
(Date:5/4/2015)... 2015   St. Jude Children,s Research Hospital ... tool for finding genetic alterations that play an ... to identify with whole-genome sequencing. The findings appear ... . The tool is an algorithm ... Regression Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... May 4, 2015  Traverse Biosciences announced today ... and development agreement (CRADA) with Aratana Therapeutics Inc. ... of TRB-N0224 for the treatment and control of ... cats.  Traverse Biosciences has also granted Aratana an ... and control of periodontal disease in companion animals, ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4
... ... Solution for German Medical Systems Biology Initiative to Study Infectious Diseases of Fungal Pathogens. ... (PRWEB) April ... and life science research, today announced that Genedata Phylosopher has been adopted by the ...
... , April 27, 2010 , ... - French Health Products Safety Agency AFSSAPS Approves ... Fatal Brain Diseases , , , ... Advanced Sterilization Products (ASP) announced today that the French,Health Products Safety Agency, ...
... , , , ... April 27 RPJ Housing, a Northern ... to persons with disabilities and life-threatening illnesses, has just completed its annual ... drew more than 1,200 volunteers, who provided an estimated $300,000 ...
Cached Biology Technology:German MedSys Project Adopts Genedata Phylosopher for Research Informatics 2German MedSys Project Adopts Genedata Phylosopher for Research Informatics 3ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions 2ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions 3ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions 4RPJ Housing's Rebuilding Together Event Brings Estimated $300,000 Worth Of Volunteer Labor to Northern VA 2
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... into chloroplasts in plants is differentially regulated by the age ... process is age-independent or only globally up- or down- regulated ... a Research Fellow from the Institute of Molecular Biology, Academia ... access journal PLOS Biology . It,s long ...
... Reserve University have found a way to create three-dimensional maps ... heart in an animal model a key to understanding ... the technology to uncover how alcohol, drugs and other factors ... humans. Passing blood cells drag on the endothelial ...
... to rice cultivation built in the middle basin of the ... various migratory dabbling duck species to significantly increase in number ... that Vegas Altas del Guadiana is turned into a new ... populations are in decline and the loss of natural wetland ...
Cached Biology News:Import of proteins into chloroplasts is differentially regulated by age 2Finding triggers of birth defects in an embryo heart 2Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
... Human CD66 acd Recognizes human ... neutrophils and cells in some cases ... with transfectants containing BGPa, NCA and ... Immunogen: Human ...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Request Info...
Biology Products: